SCHEMBL3484748

SCHEMBL3484748

CC(C)(C)OC(=O)C(C)(C)Oc1cccc(Sc2ccccc2CBr)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.37
MMP2 P08253 4/20 0.37
MMP9 P14780 4/20 0.37
MMP12 P39900 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
PPARG P37231 2/20 0.35
PPARA Q07869 2/20 0.35
MMP14 P50281 1/20 0.35
HTR1A P08908 1/20 0.35
HTR3A P46098 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
RHEB Q15382 1/20 0.34
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
FBP1 P09467 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037839 0.87 PPARG (0.44) PTGDR2MMP2MMP9MMP12SMN1; SMN2
SCHEMBL3484606 0.87 MMP2 (0.44) MMP2MMP9MMP12SMN1; SMN2SLC6A2
SCHEMBL3483947 0.82 PPARG (0.38) PPARGPPARARHEBFBP1
SCHEMBL3484445 0.78 SLC1A5 (0.40) SLC6A2SLC6A4SLC6A3PPARGPPARA
SCHEMBL3484278 0.76 PPARG (0.39) SMN1; SMN2PPARGPPARARHEBFBP1
SCHEMBL4033120 0.74 MMP2 (0.49) MMP2MMP9MMP12PPARGPPARA
SCHEMBL3484675 0.72 RIPK1 (0.41) SMN1; SMN2SLC6A2SLC6A4SLC6A3PPARG
SCHEMBL4576129 0.71 CYP1A2 (0.41) SMN1; SMN2PPARGPPARAMEN1KMT2A
SCHEMBL30609812 0.71 CYP1A2 (0.41) SMN1; SMN2PPARGPPARAMEN1KMT2A
SCHEMBL3484417 0.71 PPARA (0.40) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 PTGDR2 1386/4885MMP2 4161/4885MMP9 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.